Omnicell (NASDAQ:OMCL) had its price target raised by stock analysts at Oppenheimer to $86.00 in a note issued to investors on Friday, The Fly reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective indicates a potential upside of 23.16% from the stock’s previous close.
OMCL has been the topic of a number of other research reports. Wells Fargo & Co boosted their target price on shares of Omnicell from $59.00 to $61.00 and gave the company a “market perform” rating in a report on Monday, October 29th. Craig Hallum boosted their target price on shares of Omnicell from $65.00 to $80.00 and gave the company a “buy” rating in a report on Monday, September 17th. BidaskClub upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $80.00 target price (up previously from $70.00) on shares of Omnicell in a report on Thursday. Finally, Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Monday, August 13th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $73.75.
Shares of OMCL stock opened at $69.83 on Friday. Omnicell has a 12 month low of $39.75 and a 12 month high of $79.48. The firm has a market cap of $2.80 billion, a PE ratio of 387.94, a price-to-earnings-growth ratio of 4.22 and a beta of 0.99. The company has a current ratio of 1.78, a quick ratio of 1.32 and a debt-to-equity ratio of 0.27.
Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, beating the Zacks’ consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The firm had revenue of $204.27 million for the quarter, compared to analysts’ expectations of $203.48 million. As a group, analysts expect that Omnicell will post 1.42 earnings per share for the current year.
In other Omnicell news, Director James T. Judson sold 2,443 shares of the business’s stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $70.67, for a total value of $172,646.81. Following the completion of the transaction, the director now owns 24,952 shares of the company’s stock, valued at approximately $1,763,357.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Peter J. Kuipers sold 5,574 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $68.87, for a total value of $383,881.38. Following the completion of the transaction, the chief financial officer now directly owns 51,542 shares of the company’s stock, valued at approximately $3,549,697.54. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,267 shares of company stock worth $1,309,116. 3.71% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the business. West Coast Financial LLC raised its position in Omnicell by 3.7% in the 3rd quarter. West Coast Financial LLC now owns 115,580 shares of the company’s stock worth $8,310,000 after buying an additional 4,126 shares during the last quarter. Kopp Investment Advisors LLC raised its position in Omnicell by 2.6% in the 2nd quarter. Kopp Investment Advisors LLC now owns 69,077 shares of the company’s stock worth $3,623,000 after buying an additional 1,757 shares during the last quarter. Everence Capital Management Inc. purchased a new position in Omnicell in the 3rd quarter worth about $204,000. Janus Henderson Group PLC raised its position in Omnicell by 52.1% in the 2nd quarter. Janus Henderson Group PLC now owns 1,513,979 shares of the company’s stock worth $79,408,000 after buying an additional 518,824 shares during the last quarter. Finally, Zebra Capital Management LLC purchased a new position in Omnicell in the 2nd quarter worth about $802,000.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Recommended Story: How much money do you need to begin day trading?
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.